<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275365</url>
  </required_header>
  <id_info>
    <org_study_id>AG037547</org_study_id>
    <nct_id>NCT01275365</nct_id>
  </id_info>
  <brief_title>Optimizing Protein Intake in Older Americans With Mobility Limitations</brief_title>
  <acronym>OPTIMen</acronym>
  <official_title>Optimizing Protein Intake in Older Americans With Mobility Limitations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, placebo-controlled, parallel group, double blind, clinical trial
      in community dwelling, older men, 65 years of age or older, who have mobility limitation and
      low protein intake. The study will have a 2 X 2 factorial design, which will allow us to
      investigate the effects of dietary protein intake and testosterone separately and together.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recommended dietary allowance (RDA) for protein, set at 0.8 grams/kg/day for adult men
      and women, has engendered debate and many experts advocate protein intakes substantially
      above the RDA to help maintain muscle anabolism in older individuals. It is not known whether
      increasing protein intake in older Americans, whose current intake is below the RDA,
      increases skeletal muscle mass, muscle performance and physical function.

      Our first aim is to determine whether administration of 1.3 g/kg/day of protein, compared to
      the RDA (0.8 g/kg/day), will result in greater improvements in lean body mass, maximal
      voluntary muscle strength and power, and self-reported and performance-based measures of
      physical function in older men. Our second aim is to determine whether the gains in lean body
      mass, maximal voluntary strength and self-reported and performance-based measures of physical
      function during testosterone administration are greater with 1.3 g protein than with the RDA
      in older men on a eucaloric diet.

      We will conduct a randomized, placebo-controlled, double-blind trial using a 2 X 2 factorial
      design. Community dwelling men, 65 years or older, who have self-reported mobility
      limitation, a daily protein intake of &lt;0.8 g/kg/day and no contraindications for testosterone
      therapy, will be randomly assigned to one of four groups: placebo injections plus protein 0.8
      g/kg/day; placebo injections plus protein 1.3 g/kg/day; testosterone enanthate 100 mg weekly
      plus protein 0.8 g/kg/day; testosterone enanthate 100 mg weekly plus protein 1.3 g/kg/day.
      Treatment duration will be 6 months. The primary outcome is change in lean body mass from
      baseline to 6 months, measured by dual energy X-ray absorptiometry. Secondary outcomes
      include change in maximal voluntary strength in leg and chest press exercises, leg power,
      self-reported (physical function domain of SF-36) and performance-based measures of physical
      function (6-min walking distance and speed, stair climbing power, and load carrying),
      fatigue, well-being and affectivity balance. Safety measures include urinary calcium
      excretion, hematocrit, prostate specific antigen (PSA) and prostate examination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 19, 2017</completion_date>
  <primary_completion_date type="Actual">January 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Maximal Voluntary Strength</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Tests of Muscle Performance: (1) Maximal voluntary strength measured by 1-repetition maximum method in leg press; (2) Maximal voluntary strength in chest press; this exercise was chosen because it involves the large muscle groups of the upper extremities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Leg Press Power</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Muscle Performance measured using Power of hip and knee extension by Bassey's leg rig.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 6-minute Walking Distance</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by 6-min walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Stair Climbing Tests</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 50-meter Loaded Walking Test</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Self-reported Physical Function Domain of Short Form Health Survey (SF-36)</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Physical function domain of the Medical Outcomes Study Short Form-36 (SF-36) contains 10 items with the score range of 0-100. Higher score yields better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Psychological Well Being Index (PGWBI)</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>The PGWBI is a 22-item health-related Quality of Life (HRQoL) questionnaire developed in US which produces a self-perceived evaluation of psychological well-being expressed by a summary score. The 22 items are grouped in 6 dimensions. A global score is computed as the sum of all items with range of 0-110. A higher score yields better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Derogatis Affective Balance Scale (DABS)</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>The Derogatis Affects Balance Scale (DABS) is a multidimensional self-report mood and affects inventory comprised of 40 adjective-items using a 5-point Likert style scale. The DABS global scores consist of the Positive Total score (PTOT), Negative Total score (NTOT), where The Positive Affects Total (PTOT) is defined as the sum of all scores on the four positive affects dimensions of joy, contentment, vigor and affection, ranging 0-80. Similarly, the Negative Affects Total (NTOT) is represented as the sum of scores on the four negative dimensions of anxiety, depression, guilt and hostility, ranging 0-80. The Affects Expressiveness Index (AEI) is defined as the sum total of PTOT and NTOT, ranging 0-160. Higher score yields stronger affective intensity.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Mobility Limitation</condition>
  <arm_group>
    <arm_group_label>Placebo/Low Protein</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/High Protein</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone/Low Protein</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone/High Protein</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone enanthate</intervention_name>
    <description>Testosterone enanthate 100 mg intramuscularly weekly</description>
    <arm_group_label>Testosterone/Low Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone enanthate</intervention_name>
    <description>Testosterone enanthate 100 mg intramuscularly weekly</description>
    <arm_group_label>Testosterone/High Protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Community-dwelling men 65 years of age or older

          2. A score of 3-10 on the short physical performance battery (SPPB)

          3. Daily protein intake less than the recommended daily allowance of 0.83 g/kg/day (from
             3 24-hour food recalls)

          4. Able to give informed consent

        Exclusion Criteria:

          1. History of prostate or breast cancer

          2. American Urological Association [AUA] symptom index score of &gt;19

          3. Prostate specific antigen (PSA) &gt;4 ng/ml in White men or &gt;3 ng/ml in Black men

          4. Prostate specific antigen (PSA) &gt; 4 ng/ml in non-Black men or &gt;3 ng/ml in Black men.
             These subjects may be enrolled if they have a negative transrectal biopsy within the
             past year.

          5. Myocardial infarction or stroke within the last 6 months

          6. Uncontrolled congestive heart failure, based on the study physician's evaluation

          7. Serum creatinine &gt; 2.0 mg/dL; men on any kind of dialysis will be excluded.

          8. History of celiac disease, Crohn's disease, or ulcerative colitis

          9. History of any malignancy requiring treatment within the previous 2 years, except
             non-melanic skin cancers. Men with cancers who have not required active treatment
             within the past two years and who have not had disease recurrence within the past two
             years may be enrolled at the discretion of the study physician.

         10. Neuromuscular diseases: motor neuron diseases, multiple sclerosis, adult muscular
             dystrophies, and myasthenia gravis

         11. History of stroke with residual limb weakness that affected the individual's ability
             to walk; subjects with history of stroke who do not have residual limb weakness may be
             enrolled.

         12. Schizophrenia, bipolar disorder, or untreated diagnosed depression. Subjects with
             unipolar depression who are on an antidepressant medication are eligible.

         13. TSH levels &lt;0.4 or &gt;5 mlU/L

         14. Systolic blood pressure (BP) &gt;160 or diastolic BP &gt;100 mm Hg (average of 2
             measurements taken at Visit 1)

         15. Hemoglobin A1c &gt;8.0% or taking insulin. Men with diabetes mellitus whose A1C is less
             than 8.0% or who are not taking insulin will be eligible.

         16. Mini-Mental Status Exam [MMSE] &lt;24

         17. Body mass index (BMI) less than 20 or greater than 40 kg/m2

         18. Not willing to eat all of the following: red meat, eggs, poultry, fish and shellfish

         19. Allergy to sesame, peanuts, soy, gluten or shellfish

         20. Current alcohol use &gt;21 drinks/week based on self-report

         21. Confinement to a wheelchair

         22. Use of anabolic therapies (Testosterone, DHEA, androstenedione, rhGH) within the past
             year

         23. Current use of levodopa or anticoagulants

         24. Current enrollment in a structured weight management program or participation in any
             weight intervention studies in the last 90 days

         25. Serum ALT and AST greater than 3 x upper limit of normal

         26. Hematocrit &lt; 30% or &gt;48%

         27. Subject is not able to eat 3 frozen study meals per day for 6 months

         28. Subject is unwilling to stop current nutritional supplements

         29. Progressive intensive resistance training within 12 weeks of screening

         30. Non-compliant with run-in diet and/or supplement
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2011</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <results_first_submitted>January 19, 2018</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2018</results_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Shalendar Bhasin, MD</investigator_full_name>
    <investigator_title>Shalendar Bhasin, MD</investigator_title>
  </responsible_party>
  <keyword>Mobility Limitation</keyword>
  <keyword>Low Protein Intake</keyword>
  <keyword>Older Men</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mobility Limitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Low Protein</title>
          <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
        </group>
        <group group_id="P2">
          <title>Placebo/High Protein</title>
          <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
        </group>
        <group group_id="P3">
          <title>Testosterone/Low Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
        <group group_id="P4">
          <title>Testosterone/High Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Low Protein</title>
          <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
        </group>
        <group group_id="B2">
          <title>Placebo/High Protein</title>
          <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
        </group>
        <group group_id="B3">
          <title>Testosterone/Low Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
        <group group_id="B4">
          <title>Testosterone/High Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="92"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="4.2"/>
                    <measurement group_id="B2" value="73.5" spread="5.7"/>
                    <measurement group_id="B3" value="71.0" spread="3.6"/>
                    <measurement group_id="B4" value="76.0" spread="7.9"/>
                    <measurement group_id="B5" value="73.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.3" spread="12.5"/>
                    <measurement group_id="B2" value="90.2" spread="15.8"/>
                    <measurement group_id="B3" value="94.4" spread="17.6"/>
                    <measurement group_id="B4" value="87.2" spread="18.3"/>
                    <measurement group_id="B5" value="91.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="4.2"/>
                    <measurement group_id="B2" value="29.6" spread="4.6"/>
                    <measurement group_id="B3" value="31.4" spread="5.5"/>
                    <measurement group_id="B4" value="29.0" spread="5.0"/>
                    <measurement group_id="B5" value="30.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="22"/>
                    <count group_id="B4" value="22"/>
                    <count group_id="B5" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)</title>
        <description>Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA)</title>
          <description>Primary outcome is change in lean body mass, measured by dual energy X-ray absorptiometry (DXA)</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.31"/>
                    <measurement group_id="O2" value="0.74" spread="0.33"/>
                    <measurement group_id="O3" value="4.43" spread="0.48"/>
                    <measurement group_id="O4" value="4.13" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Maximal Voluntary Strength</title>
        <description>Tests of Muscle Performance: (1) Maximal voluntary strength measured by 1-repetition maximum method in leg press; (2) Maximal voluntary strength in chest press; this exercise was chosen because it involves the large muscle groups of the upper extremities.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Maximal Voluntary Strength</title>
          <description>Tests of Muscle Performance: (1) Maximal voluntary strength measured by 1-repetition maximum method in leg press; (2) Maximal voluntary strength in chest press; this exercise was chosen because it involves the large muscle groups of the upper extremities.</description>
          <units>newton</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximal voluntary strength in leg press</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.6" spread="46.4"/>
                    <measurement group_id="O2" value="156.0" spread="89.1"/>
                    <measurement group_id="O3" value="201.8" spread="44.4"/>
                    <measurement group_id="O4" value="191.4" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal voluntary strength in chest press</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="12.3"/>
                    <measurement group_id="O2" value="16.6" spread="9.2"/>
                    <measurement group_id="O3" value="64.5" spread="11.9"/>
                    <measurement group_id="O4" value="59.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Leg Press Power</title>
        <description>Muscle Performance measured using Power of hip and knee extension by Bassey's leg rig.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Leg Press Power</title>
          <description>Muscle Performance measured using Power of hip and knee extension by Bassey's leg rig.</description>
          <units>watts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="17.0"/>
                    <measurement group_id="O2" value="96.9" spread="19.6"/>
                    <measurement group_id="O3" value="61.5" spread="22.2"/>
                    <measurement group_id="O4" value="81.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of 6-minute Walking Distance</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by 6-min walking distance</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of 6-minute Walking Distance</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by 6-min walking distance</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="17.9"/>
                    <measurement group_id="O2" value="49.9" spread="14.2"/>
                    <measurement group_id="O3" value="38.2" spread="21.9"/>
                    <measurement group_id="O4" value="25.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Stair Climbing Tests</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Stair Climbing Tests</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry.</description>
          <units>watts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unloaded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="19.2"/>
                    <measurement group_id="O2" value="55.4" spread="14.2"/>
                    <measurement group_id="O3" value="53.2" spread="17.5"/>
                    <measurement group_id="O4" value="4.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loaded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="15.7"/>
                    <measurement group_id="O2" value="83.7" spread="28.5"/>
                    <measurement group_id="O3" value="56.6" spread="18.8"/>
                    <measurement group_id="O4" value="26.9" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of 50-meter Loaded Walking Test</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of 50-meter Loaded Walking Test</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry.</description>
          <units>meters per second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.04"/>
                    <measurement group_id="O2" value="0.11" spread="0.05"/>
                    <measurement group_id="O3" value="0.06" spread="0.05"/>
                    <measurement group_id="O4" value="0.08" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Self-reported Physical Function Domain of Short Form Health Survey (SF-36)</title>
        <description>36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Physical function domain of the Medical Outcomes Study Short Form-36 (SF-36) contains 10 items with the score range of 0-100. Higher score yields better performance.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Self-reported Physical Function Domain of Short Form Health Survey (SF-36)</title>
          <description>36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Physical function domain of the Medical Outcomes Study Short Form-36 (SF-36) contains 10 items with the score range of 0-100. Higher score yields better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="3.1"/>
                    <measurement group_id="O2" value="-5.5" spread="5.3"/>
                    <measurement group_id="O3" value="2.1" spread="2.8"/>
                    <measurement group_id="O4" value="-2.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Psychological Well Being Index (PGWBI)</title>
        <description>The PGWBI is a 22-item health-related Quality of Life (HRQoL) questionnaire developed in US which produces a self-perceived evaluation of psychological well-being expressed by a summary score. The 22 items are grouped in 6 dimensions. A global score is computed as the sum of all items with range of 0-110. A higher score yields better performance.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Psychological Well Being Index (PGWBI)</title>
          <description>The PGWBI is a 22-item health-related Quality of Life (HRQoL) questionnaire developed in US which produces a self-perceived evaluation of psychological well-being expressed by a summary score. The 22 items are grouped in 6 dimensions. A global score is computed as the sum of all items with range of 0-110. A higher score yields better performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="1.53"/>
                    <measurement group_id="O2" value="1.17" spread="1.77"/>
                    <measurement group_id="O3" value="0.32" spread="2.08"/>
                    <measurement group_id="O4" value="2.68" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</title>
        <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individuals level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</title>
          <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individuals level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="1.56"/>
                    <measurement group_id="O2" value="-0.14" spread="1.41"/>
                    <measurement group_id="O3" value="-0.53" spread="1.39"/>
                    <measurement group_id="O4" value="1.05" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Derogatis Affective Balance Scale (DABS)</title>
        <description>The Derogatis Affects Balance Scale (DABS) is a multidimensional self-report mood and affects inventory comprised of 40 adjective-items using a 5-point Likert style scale. The DABS global scores consist of the Positive Total score (PTOT), Negative Total score (NTOT), where The Positive Affects Total (PTOT) is defined as the sum of all scores on the four positive affects dimensions of joy, contentment, vigor and affection, ranging 0-80. Similarly, the Negative Affects Total (NTOT) is represented as the sum of scores on the four negative dimensions of anxiety, depression, guilt and hostility, ranging 0-80. The Affects Expressiveness Index (AEI) is defined as the sum total of PTOT and NTOT, ranging 0-160. Higher score yields stronger affective intensity.</description>
        <time_frame>6 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Low Protein</title>
            <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
          </group>
          <group group_id="O2">
            <title>Placebo/High Protein</title>
            <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
          </group>
          <group group_id="O3">
            <title>Testosterone/Low Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
          <group group_id="O4">
            <title>Testosterone/High Protein</title>
            <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Derogatis Affective Balance Scale (DABS)</title>
          <description>The Derogatis Affects Balance Scale (DABS) is a multidimensional self-report mood and affects inventory comprised of 40 adjective-items using a 5-point Likert style scale. The DABS global scores consist of the Positive Total score (PTOT), Negative Total score (NTOT), where The Positive Affects Total (PTOT) is defined as the sum of all scores on the four positive affects dimensions of joy, contentment, vigor and affection, ranging 0-80. Similarly, the Negative Affects Total (NTOT) is represented as the sum of scores on the four negative dimensions of anxiety, depression, guilt and hostility, ranging 0-80. The Affects Expressiveness Index (AEI) is defined as the sum total of PTOT and NTOT, ranging 0-160. Higher score yields stronger affective intensity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Affects Expressiveness Index (AEI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="3.54"/>
                    <measurement group_id="O2" value="1.45" spread="1.96"/>
                    <measurement group_id="O3" value="-0.50" spread="2.51"/>
                    <measurement group_id="O4" value="-3.17" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Total score (PTOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="2.09"/>
                    <measurement group_id="O2" value="2.10" spread="1.70"/>
                    <measurement group_id="O3" value="0.69" spread="1.68"/>
                    <measurement group_id="O4" value="1.89" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Total score (NTOT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="2.03"/>
                    <measurement group_id="O2" value="-0.65" spread="1.36"/>
                    <measurement group_id="O3" value="-0.88" spread="2.85"/>
                    <measurement group_id="O4" value="-5.53" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Low Protein</title>
          <description>Placebo injections weekly; 0.8 g/kg/day protein</description>
        </group>
        <group group_id="E2">
          <title>Placebo/High Protein</title>
          <description>Placebo injections weekly; 1.3 g/kg/day protein</description>
        </group>
        <group group_id="E3">
          <title>Testosterone/Low Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
        <group group_id="E4">
          <title>Testosterone/High Protein</title>
          <description>Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
Testosterone enanthate: Testosterone enanthate 100 mg intramuscularly weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Inner ear problem</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic/Lymphatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endorine/Metabolic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious Disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genital/Urinary</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shalendar Bhasin, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-525-9040</phone>
      <email>Sbhasin@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

